The Impact of HealthTech on Pharmaceutical Manufacturing

July 28, 2024

Pharmaceutical manufacturing is a complex and highly regulated industry essential for producing medications that meet strict safety and efficacy standards. This industry involves the synthesis of chemical compounds, formulation development, quality control, and the mass production of pharmaceutical products. It is a cornerstone of global healthcare, providing the necessary drugs and therapies that improve and save lives.


Health technology (HealthTech) is revolutionizing pharmaceutical manufacturing by introducing innovative tools and methodologies that enhance efficiency, accuracy, and scalability. These technologies address longstanding challenges in the industry, such as high production costs, stringent regulatory requirements, and the need for rapid drug development. By integrating advanced technologies like artificial intelligence (AI), the Internet of Things (IoT), automation, and blockchain, HealthTech is poised to transform pharmaceutical manufacturing, making it more agile and responsive to market demands.

This blog aims to explore how HealthTech innovations are transforming pharmaceutical manufacturing and to highlight the investment opportunities these advancements present. We will delve into the specifics of various technologies, their benefits, and real-world applications, providing a comprehensive overview of the current landscape and future trends.


Understanding Pharmaceutical Manufacturing

Pharmaceutical manufacturing encompasses the entire process of drug production, from the initial discovery and development stages to the large-scale production and packaging of medications. This process includes:


  1. Drug Discovery and Development: Identifying and synthesizing new compounds that have therapeutic potential.
  2. Formulation Development: Creating the drug product in a form that can be administered to patients, such as tablets, capsules, or injectables.
  3. Quality Control and Assurance: Ensuring that the drug meets all regulatory standards for safety, efficacy, and quality.
  4. Mass Production: Scaling up the production process to manufacture large quantities of the drug.


Key Processes Involved in Pharmaceutical Manufacturing

Pharmaceutical manufacturing involves several critical processes, including:


  • Chemical Synthesis: Creating the active pharmaceutical ingredient (API) through chemical reactions.
  • Formulation and Compounding: Combining the API with excipients to create the final drug product.
  • Packaging: Encasing the drug in appropriate containers to ensure stability and facilitate distribution.
  • Quality Control: Conducting tests to ensure the drug meets all specifications and regulatory requirements.


Challenges Faced by the Pharmaceutical Manufacturing Industry

The pharmaceutical manufacturing industry faces numerous challenges, such as:


  • High Costs: The development and production of new drugs require significant financial investment.
  • Regulatory Compliance: Navigating complex regulatory requirements to ensure drug safety and efficacy.
  • Supply Chain Management: Ensuring a reliable supply of raw materials and managing distribution logistics.
  • Technological Complexity: Adapting to rapidly evolving technologies and integrating them into existing processes.


The Role of HealthTech in Pharmaceutical Manufacturing


HealthTech is addressing these challenges by introducing technologies that enhance every aspect of pharmaceutical manufacturing, from drug discovery to production and distribution. These innovations streamline processes, improve accuracy, and reduce costs, ultimately leading to better patient outcomes.


Artificial Intelligence (AI)

AI and machine learning algorithms analyze vast amounts of data to identify potential drug candidates, optimize manufacturing processes, and predict outcomes. These technologies enable faster and more accurate decision-making, reducing the time and cost associated with drug development.


Internet of Things (IoT)

IoT devices collect real-time data from manufacturing equipment and processes, enabling continuous monitoring and optimization. This data-driven approach improves efficiency, reduces downtime, and enhances product quality.


Automation

Automation technologies, including robotics and advanced manufacturing systems, streamline production processes and reduce human error. Automated systems can handle repetitive tasks with precision, increasing productivity and consistency.


Blockchain

Blockchain technology ensures transparency and security in the pharmaceutical supply chain. By providing a tamper-proof record of transactions, blockchain helps prevent counterfeiting, ensures product integrity, and facilitates regulatory compliance.


Examples of HealthTech Applications in Pharmaceutical Manufacturing


HealthTech applications in pharmaceutical manufacturing are numerous and varied. For example, AI-driven platforms like IBM Watson are used for drug discovery and development, while IoT devices monitor equipment performance and environmental conditions in real-time. Automation technologies, such as robotic arms and automated packaging systems, enhance production efficiency, and blockchain solutions like MediLedger ensure the integrity of the supply chain.


HealthTech Innovations in Pharmaceutical Manufacturing


AI and Machine Learning: Enhancing Drug Discovery and Development

AI and machine learning are transforming drug discovery and development by analyzing complex datasets to identify promising drug candidates and predict their efficacy. These technologies accelerate the research process, reduce costs, and increase the likelihood of successful outcomes.


IoT and Smart Manufacturing: Improving Efficiency and Monitoring

IoT devices collect and analyze data from manufacturing equipment, providing real-time insights into performance and efficiency. This continuous monitoring helps identify potential issues before they become critical, reducing downtime and improving product quality.


Automation and Robotics: Streamlining Production Processes

Automation and robotics streamline production processes by performing repetitive tasks with precision and consistency. Automated systems reduce human error, increase productivity, and enhance overall manufacturing efficiency.


Blockchain: Ensuring Supply Chain Transparency and Security

Blockchain technology provides a secure and transparent record of transactions throughout the pharmaceutical supply chain. This ensures the authenticity of products, prevents counterfeiting, and facilitates regulatory compliance.


Examples of Successful Implementations and Their Impact on Manufacturing Processes

Several companies have successfully implemented HealthTech solutions in their manufacturing processes. For example:


  • Pfizer: Pfizer uses AI to streamline drug discovery and development, significantly reducing the time and cost associated with bringing new drugs to market.
  • Novartis: Novartis employs IoT devices to monitor and optimize manufacturing processes, improving efficiency and product quality.
  • Johnson & Johnson: Johnson & Johnson has integrated automation and robotics into their production lines, enhancing productivity and reducing human error.
  • Roche: Roche utilizes blockchain technology to ensure the integrity of their supply chain, preventing counterfeiting and ensuring regulatory compliance.


Benefits of HealthTech in Pharmaceutical Manufacturing


Improved Efficiency and Productivity

HealthTech innovations improve efficiency and productivity by streamlining processes, reducing downtime, and optimizing resource use. Automated systems and real-time data monitoring enable manufacturers to produce more drugs in less time, reducing costs and increasing output.


Enhanced Quality Control and Compliance

HealthTech solutions enhance quality control by providing continuous monitoring and data analysis. This ensures that products meet all regulatory standards and reduces the risk of errors and defects. Blockchain technology also enhances compliance by providing a secure and transparent record of all transactions.


Cost Savings and Resource Optimization

HealthTech innovations reduce costs by optimizing resource use and improving efficiency. Automated systems and AI-driven processes minimize waste and reduce the need for manual labor, resulting in significant cost savings.


Accelerated Drug Development and Time-to-Market

AI and machine learning accelerate drug discovery and development by identifying promising candidates and predicting their efficacy. This reduces the time and cost associated with bringing new drugs to market, allowing manufacturers to respond more quickly to market demands.


Case Studies of HealthTech Solutions in Pharmaceutical Manufacturing


Case Study 1: AI-Driven Drug Discovery and Its Impact on Production

A pharmaceutical company used AI to analyze vast amounts of data and identify potential drug candidates. The AI platform significantly reduced the time and cost of drug discovery, leading to the successful development of a new treatment. This innovation not only improved efficiency but also increased the likelihood of successful outcomes.


Case Study 2: Implementation of IoT in Smart Manufacturing Facilities

A pharmaceutical manufacturer implemented IoT devices to monitor equipment performance and environmental conditions in real-time. This data-driven approach improved efficiency, reduced downtime, and enhanced product quality. The IoT solution also provided valuable insights for optimizing processes and resource use.


Case Study 3: Automation and Robotics in Pharmaceutical Production

A pharmaceutical company integrated automation and robotics into their production lines, streamlining processes and reducing human error. The automated systems performed repetitive tasks with precision and consistency, increasing productivity and enhancing overall manufacturing efficiency.


Lessons Learned from These Case Studies

These case studies demonstrate the significant benefits of HealthTech solutions in pharmaceutical manufacturing. By leveraging advanced technologies, companies can improve efficiency, enhance quality control, reduce costs, and accelerate drug development. However, successful implementation requires careful planning, continuous monitoring, and a commitment to innovation.


Challenges and Risks


Potential Challenges and Risks in Adopting HealthTech in Pharmaceutical Manufacturing

Despite the significant benefits, adopting HealthTech in pharmaceutical manufacturing presents several challenges and risks. These include:

  • Technical and Operational Challenges: Implementing new technologies requires significant investment in infrastructure and training. Companies must also ensure compatibility with existing systems and processes.
  • Regulatory and Compliance Hurdles: Navigating complex regulatory requirements can be challenging, particularly for new technologies. Companies must ensure compliance with all relevant regulations and standards.
  • Cost and Accessibility Issues: The high cost of implementing advanced technologies can be a barrier, particularly for smaller companies. Ensuring equitable access to these technologies is also a concern.


Strategies for Overcoming These Challenges

To overcome these challenges, companies can:

  • Invest in Training and Education: Providing comprehensive training for employees ensures they can effectively use new technologies.
  • Collaborate with Regulatory Bodies: Working closely with regulatory agencies can help companies navigate compliance requirements and ensure their technologies meet all necessary standards.
  • Leverage Partnerships and Collaborations: Collaborating with other companies, research institutions, and technology providers can help share the costs and risks associated with implementing new technologies.


Investment Opportunities in HealthTech for Pharmaceutical Manufacturing


Identifying Promising HealthTech Companies and Technologies for Pharmaceutical Manufacturing

Investors should look for companies with strong research pipelines, experienced management teams, and a track record of innovation. Promising technologies include AI-driven drug discovery platforms, IoT-enabled smart manufacturing solutions, advanced automation and robotics systems, and blockchain solutions for supply chain management.


Factors to Consider When Investing in This Field

When investing in HealthTech for pharmaceutical manufacturing, consider factors such as:

  • Market Potential: Assess the market demand for the technology and its potential for growth.
  • Regulatory Environment: Understand the regulatory landscape and ensure the company can navigate compliance requirements.
  • Technology Maturity: Evaluate the technology's readiness for commercial use and its compatibility with existing systems.
  • Financial Stability: Assess the company's financial health and its ability to sustain long-term growth.


Long-Term vs. Short-Term Investment Strategies

Investing in HealthTech for pharmaceutical manufacturing often requires a long-term perspective due to the lengthy development and approval timelines for new technologies. However, short-term opportunities may arise from partnerships, acquisitions, or regulatory approvals.


Examples of Recent Investments and Their Outcomes

Recent investments in HealthTech for pharmaceutical manufacturing have yielded significant returns. For example, venture capital firms have invested in AI-driven drug discovery platforms, resulting in the development of promising new treatments. Similarly, investments in IoT-enabled smart manufacturing solutions have improved efficiency and product quality, leading to increased profitability.


Future Trends and Innovations


Emerging Trends and Future Directions in HealthTech for Pharmaceutical Manufacturing

Emerging trends in HealthTech for pharmaceutical manufacturing include:


  • Advanced AI and Machine Learning: Continued advancements in AI and machine learning will further enhance drug discovery, development, and manufacturing processes.
  • Integration of IoT and Blockchain: Combining IoT and blockchain technologies will enhance supply chain transparency, security, and efficiency.
  • Personalized Medicine: Advances in genetic testing and personalized treatment approaches will drive the development of targeted therapies.
  • Sustainable Manufacturing: Innovations in sustainable manufacturing practices will reduce the environmental impact of pharmaceutical production.


The Impact of Technological Advancements on Pharmaceutical Manufacturing

Technological advancements will continue to transform pharmaceutical manufacturing, making it more efficient, agile, and responsive to market demands. These innovations will improve product quality, reduce costs, and accelerate drug development, ultimately benefiting patients and healthcare systems worldwide.


Predictions for the Next Decade in HealthTech for Pharmaceutical Manufacturing

Over the next decade, we can expect to see:


  • Increased Adoption of AI and Automation: AI and automation technologies will become integral to pharmaceutical manufacturing, enhancing efficiency and accuracy.
  • Expansion of IoT-Enabled Smart Manufacturing: IoT devices will be widely used to monitor and optimize manufacturing processes in real-time.
  • Widespread Implementation of Blockchain: Blockchain solutions will ensure supply chain transparency and security, preventing counterfeiting and ensuring regulatory compliance.
  • Growth of Personalized Medicine: Personalized treatment approaches will become more prevalent, driven by advances in genetic testing and data analytics.


Conclusion


HealthTech innovations are transforming pharmaceutical manufacturing, addressing longstanding challenges and improving efficiency, quality, and cost-effectiveness. Technologies such as AI, IoT, automation, and blockchain are driving significant advancements in drug discovery, development, and production.

The integration of HealthTech into pharmaceutical manufacturing holds immense potential for improving patient outcomes, enhancing operational efficiency, and reducing costs. By embracing these technologies, pharmaceutical companies can stay competitive in a rapidly evolving industry and meet the growing demand for safe and effective medications.


Investing in HealthTech solutions for pharmaceutical manufacturing presents significant opportunities for financial returns and social impact. By supporting innovative companies and technologies, investors can contribute to the advancement of healthcare and improve the lives of millions of patients worldwide.

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts